➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Baxter
Express Scripts
Boehringer Ingelheim

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 10,323,013

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,323,013
Title:Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
Abstract: Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1P1.
Inventor(s): Del Valle; Juan R. (Tampa, FL), Hu; Chih-Chi Andrew (Tampa, FL)
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL)
Application Number:14/786,561
Patent Claims:see list of patent claims

Details for Patent 10,323,013

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL) 2033-04-23 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL) 2033-04-23 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL) 2033-04-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Express Scripts
Mallinckrodt
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.